Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.